Parkview Research Center
Parkview Research Center
Fort Wayne, Indiana, United States17 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05702034 | |
| A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 | 2026-09-15 | NCT07023627 | |
| Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia | Barrett esophagus, Digestive System Diseases, digestive system disorder, esophageal adenocarcinoma, esophageal disorder, neoplasm, precancerous condition | Recruiting | Not applicable | 2026-09-11 | NCT05753748 | |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, coronary artery disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Recruiting | Phase 3 | 2026-08-21 | NCT07136012 | |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Recruiting | Phase 3 | 2026-08-12 | NCT06801834 | |
| Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 3 | 2026-07-28 | NCT07022483 | |
| Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | small intestine adenocarcinoma | Recruiting | Phase 2 | 2026-07-28 | NCT06835387 | |
| Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | hormone receptor-positive breast cancer | Recruiting | Phase 2 | 2026-07-16 | NCT05467891 | |
| Integrated Cancer Repository for Cancer Research | Abdominal Neoplasms, Adenomatous Polyps, Adnexal Diseases, Anal Cancer, Biliary Tract Neoplasms, Blood Protein Disorders, Colorectal Neoplasms, Hereditary Nonpolyposis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cronkhite-Canada syndrome, DNA repair disease, Digestive System Diseases, Digestive System Neoplasms, Duodenal Cancer, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Liver Neoplasms, Lynch syndrome, Male Urogenital Diseases, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplasms, Unknown Primary, Neoplastic Processes, Nose Neoplasms, Nutritional and Metabolic Diseases, Otorhinolaryngologic Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Peritoneal Diseases, Peritoneal Surface Malignancy, Pharyngeal Diseases, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Thymus Neoplasms, Thyroid Nodule, Unknown Primary Tumors, Urogenital Diseases, Urogenital Neoplasms, adenoma, anus disorder, anus neoplasm, benign urinary system neoplasm, bile duct cancer, bile duct disorder, bile duct neoplasm, biliary tract disorder, breast cancer, breast disorder, breast neoplasm, cardiovascular disorder, central nervous system cancer, classic familial adenomatous polyposis, colonic disorder, colonic neoplasm, colorectal neoplasm, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, duodenal disorder, duodenum cancer, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gallbladder disorder, gallbladder neoplasm, gastric cancer, gastric neoplasm, gastrointestinal stromal tumor, gonadal disorder, hematologic disorder, hemorrhagic disease, hereditary disease, hereditary neoplastic syndrome, hypopharynx cancer, immune system disorder, immunoproliferative disorder, intestinal disorder, kidney cancer, kidney disorder, laryngeal disorder, laryngeal neoplasm, larynx cancer, leukemia, lip cancer, lip disorder, liver cancer, liver disorder, lung cancer, lung disorder, lung neoplasm, lymphatic system disorder, lymphoproliferative syndrome, male reproductive organ cancer, male reproductive system disorder, malignant colon neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, malignant tumor of nasopharynx, melanocytic neoplasm, melanoma, mesothelial neoplasm, mesothelioma, metabolic disease, monoclonal gammopathy, mouth disorder, nasal cavity cancer, nasal disorder, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, nervous system disorder, neuroendocrine neoplasm, oral cavity cancer, otorhinolaryngologic disease, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, paranasal sinus cancer, paranasal sinus disorder, paranasal sinus neoplasm, penile cancer, penile disorder, penile neoplasm, peritoneal neoplasm, plasma cell neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, rectal cancer, rectal disorder, rectal neoplasm, respiratory system disorder, respiratory tract neoplasm, salivary gland cancer, salivary gland disorder, sarcoma, skin disorder, skin neoplasm, small intestine cancer, stomach disorder, testicular cancer, testicular disorder, thymus cancer, thyroid gland disorder, thyroid tumor, ureter cancer, ureteral disorder, urethra neoplasm, urethral disorder, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder, vaginal cancer, vaginal disorder, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-06-29 | NCT02012699 | |
| Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Active, not recruiting | Phase 3 | 2026-06-15 | NCT05653349 | |
| An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-06-08 | NCT04720157 | |
| Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 4 | 2026-06-04 | NCT05803941 | |
| Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Active, not recruiting | Phase 2 | 2026-04-28 | NCT03964727 | |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | Abdominal Neoplasms, Adnexal Diseases, Carcinoma, Ovarian Epithelial, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Peritoneal Diseases, Urogenital Diseases, Urogenital Neoplasms, carcinoma, endocrine system disorder, epithelial neoplasm, fallopian tube adenocarcinoma, fallopian tube disorder, fallopian tube neoplasm, fallopian tube serous adenocarcinoma, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, ovarian serous adenocarcinoma, peritoneal carcinoma, peritoneal neoplasm, peritoneum cancer | Active, not recruiting | Phase 3 | 2026-04-01 | NCT04498117 | |
| Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement | Arterial Occlusive Diseases, Ventricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, heart valve disorder, myocardial ischemia, vascular disorder | Recruiting | Not applicable | 2025-07-24 | NCT04634240 | |
| RADIANCE Continued Access Protocol | Hypertension Resistant to Conventional Therapy, cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Active, not recruiting | Not applicable | 2024-06-17 | NCT05017935 | |
| Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 2 / Phase 3 | 2024-05-02 | NCT05797831 |